|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/02/24 Cigna Group 8-K:2,9 5/02/24 11:378K Scullin Group, Inc./FA |
Document/Exhibit Description Pages Size 1: 8-K The Cigna Group Form 8-K HTML 27K 2: EX-99.1 Miscellaneous Exhibit HTML 164K 6: R1 Cover HTML 45K 8: XML IDEA XML File -- Filing Summary XML 11K 11: XML XBRL Instance -- cigna8k_htm XML 16K 7: EXCEL IDEA Workbook of Financial Report Info XLSX 8K 4: EX-101.LAB XBRL Labels -- ci-20240502_lab XML 96K 5: EX-101.PRE XBRL Presentations -- ci-20240502_pre XML 64K 3: EX-101.SCH XBRL Schema -- ci-20240502 XSD 12K 9: JSON XBRL Instance as JSON Data -- MetaLinks 25± 34K 10: ZIP XBRL Zipped Folder -- 0000950159-24-000134-xbrl Zip 37K
| The Cigna Group Earnings 8-K |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) i May 2, 2024
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction of
incorporation) |
i 001-38769 (Commission File Number) |
i 82-4991898 (IRS Employer Identification No.) |
i Bloomfield, i Connecticut i 06002
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
i ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| i Common Stock, Par Value $0.01 | i CI | i New York Stock Exchange, Inc. |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. |
On May 2, 2024, The Cigna Group issued a press release announcing results for the three months ended March 31, 2024. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
The Evernorth Health Services reportable segment now presents the Pharmacy Benefit Services and the Specialty and Care Services operating segments, which partner with health plans, employers, governmental organizations and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. For additional information relating to our operating segments, please refer to Note 1 to the Consolidated Financial Statements in our quarterly report on Form 10-Q for the period ended March 31, 2024, which is expected to be filed today with the Securities and Exchange Commission. Unaudited supplemental 2023 information for Evernorth Health Services, as restated for the operating segment change, is included in our Quarterly Financial Supplement for the period ended March 31, 2024, available through the Investor Relations page of the Company’s website located at www.thecignagroup.com. The information on our website is not, and shall not be deemed to be, part of this Current Report on Form 8-K or incorporated herein.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date of this Current Report on Form 8-K, except as shall be expressly set forth by specific reference in such a filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description |
| 99.1 | Press release dated May 2, 2024. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| THE CIGNA GROUP | ||
| Date: May 2, 2024 | By: | /s/ Brian C. Evanko |
| Brian C. Evanko | ||
| Executive Vice President, Chief Financial Officer, The Cigna Group, and President and Chief Executive Officer, Cigna Healthcare | ||
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / For Period end: | 5/2/24 | None on these Dates | ||
| 3/31/24 | ||||
| List all Filings | ||||